SCHEMBL2496190

SCHEMBL2496190

Cc1c(Cl)ccc2c1C(=O)C(=O)N2

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CES1 P23141 13/20 0.67
▸ TGM2 P21980 3/20 0.43
▸ MEN1 O00255 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ DUSP3 P51452 1/20 0.38
▸ BLM P54132 1/20 0.38
▸ PTPN5 P54829 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ PTPN11 Q06124 1/20 0.38
▸ MCL1 Q07820 1/20 0.38
▸ CTDSP1 Q9GZU7 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ MAOA P21397 3/20 0.36
▸ MAOB P27338 3/20 0.36
▸ ROS1 P08922 1/20 0.36
▸ CDK5 Q00535 1/20 0.36
▸ ACVR1 Q04771 1/20 0.36
▸ LRRK2 Q5S007 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL734955 0.80 CES1 (1.00) CES1TGM2MEN1POLBMAPT
SCHEMBL3743988 0.80 CES1 (0.50) CES1TGM2MEN1POLBMAPT
SCHEMBL29253561 0.78 CES1 (0.69) CES1TGM2MEN1POLBMAPT
SCHEMBL3391317 0.77 CES1 (0.67) CES1TGM2MEN1POLBMAPT
SCHEMBL30838472 0.77 CES1 (0.47) CES1TGM2MEN1POLBMAPT
SCHEMBL3736279 0.77 CES1 (0.47) CES1TGM2MEN1POLBMAPT
SCHEMBL29700199 0.77 CES1 (0.47) CES1TGM2MEN1POLBMAPT
SCHEMBL15353216 0.77 CES1 (0.47) CES1TGM2MEN1POLBMAPT
SCHEMBL29446052 0.77 CES1 (0.67) CES1TGM2MEN1POLBMAPT
SCHEMBL19260393 0.77 CES1 (0.67) CES1TGM2MEN1POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8030499-B2 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-10-04 — — US disclosed
US-7528124-B2 1,3-dihydro-2H-indol-2-one derivative TAISHO PHARMACEUTICAL CO., LTD. (JP) 2009-05-05 — — US disclosed
US-20080318923-A1 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle TAISHO PHARMACEUTICAL CO., LTD. (JP) 2008-12-25 — — US disclosed
US-20060276449-A1 1,3-Dihydro-2h-indol-2-one derivative TAISHO PHARMACEUTICAL CO., LTD. (JP) 2006-12-07 — — US disclosed
EP-1659121-A1 1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD (JP) 2006-05-24 — — EP disclosed
WO-2003106435-A1 FUSED-RING PYRIMIDIN-4(3H)-ONE DERIVATIVES, PROCESSES FOR THE PREPARATION AND USES THEREOF SANKYO COMPANY, LIMITED (JP) 2003-12-24 — — WO disclosed
EP-0002624-B1 2-BENZAZEPINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SMITHKLINE BECKMAN CORPORATION (US) 1981-10-14 — — EP disclosed
EP-0002624-A1 2-Benzazepine compounds, processes for their preparation and pharmaceutical compositions containing them SMITHKLINE BECKMAN CORPORATION (US) 1979-06-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276449-A1 1,3-Dihydro-2h-indol-2-one derivative AVPR1B, AVPR2, AVPR1A CES1 3689/4885TGM2 4857/4885MEN1 353/4885
US-20080318923-A1 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle AVPR1B, AVPR1A, AVPR2 CES1 3264/4885TGM2 3073/4885MEN1 527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback